Conference Proceedings

Increased Eligibility for Attempting Treatment-Free Remission (TFR) with Frontline Nilotinib (NIL) vs Imatinib (IM) in Patients with Philadelphia Chromosome-Positive (Ph plus ) Chronic Myeloid Leukemia (CML): Results of a Stochastic Simulation Model

Francois-Xavier Mahon, An Tran-Duy, Raechelle G Ocampo, David Ray, Estella Mendelson, Aby Buchbinder, Pascal Edrich, Sonya J Snedecor, Giuseppe Saglio

BLOOD | AMER SOC HEMATOLOGY | Published : 2015